S 4106: Rx ACCESS Act - United States

S 4106 – Rx ACCESS Act

Senate Bill No. 4106 – Rx Access, Choice, Cost Equity, and Supply Stability Act

Introduced: March 17, 2026

Status: Introduced in Senate, referred to the Judiciary Committee

1. Purpose & Intent

The Rx ACCESS Act is designed to improve access to prescription medications, broaden patient choice, promote price equity, and stabilize drug supplies. While the full text of the bill is not yet available, the title suggests a comprehensive approach aimed at addressing key pain points in the U.S. pharmacy system:

Access – Removing barriers that prevent timely and affordable medication for patients.
Choice – Encouraging competition among providers and fostering patient‑centered decision making.
Cost Equity – Aiming for fair pricing structures across socioeconomic groups.
Supply Stability – Establishing safeguards against shortages and ensuring reliable availability of essential drugs.

2. Key Provisions (as outlined by title and legislative intent)

Area	Likely Focus	Possible Priorities
Access	Expand coverage under public and private plans	Implement automatic coverage for essential drugs
Choice	Promote generic substitution, allow alternative dispensing options	Mandate prescriber‐ and pharmacy‑level transparency
Cost Equity	Address geographic and income‑based disparities in drug pricing	Introduce price‑cap mechanisms and price‑indexing
Supply Stability	Increase oversight of drug manufacturing and distribution	Create early‑warning systems for shortages and require contingency plans

Note: The Senate brief on S 4106 provides no explicit text beyond the title and procedural history. Thus, the above table reflects inferred priorities rather than codified language.

3. Stakeholders & Impact

Group	Potential Impact
Patients	Greater access to medications, potentially lower out‑of‑pocket costs, more options for treatment.
Pharmacies	Opportunity to diversify services, but may face new regulatory requirements to comply with supply‑stability mandates.
Pharmaceutical Companies	Possible new oversight on pricing and supply chain reporting; incentive for innovation in cost‑effective therapies.
Health Insurers	Adjustments to benefit designs and formulary management; potential cost savings from price‑equity measures.
Payers & Regulators	Enhanced data collection on drug pricing and availability; need for coordination across federal agencies.

4. Procedural Timeline

March 17, 2026 – Read twice in the Senate; referred to the Committee on the Judiciary.
Subsequent actions will include committee markup, potential hearings, and reporting.
If reported favorably, the bill will move to floor consideration, where it may be debated, amended, and eventually voted on.

5. Sponsors & Related Legislation

Sponsors:
- Sen. Timothy M. Kaine (D‑VA)
- Sen. Tom Cotton (R‑AR)
- Sen. Shelley Moore Capito (R‑WV)
Related Bill: House Resolution 6400 (companion bill in the House of Representatives).

Bottom Line

The Rx ACCESS Act is an early‑stage effort focused on enhancing medication accessibility, fostering patient choice, ensuring equitable cost structures, and bolstering supply chain resilience. As the bill moves through the Senate Judiciary Committee, detailed provisions will emerge that will clarify the specific mechanisms and regulatory changes it proposes. Stakeholders should monitor upcoming committee actions for more concrete information.

Rx ACCESS Act